688247 宣泰医药
已收盘 12-12 15:00:00
资讯
新帖
简况
宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%
证券之星 · 12-12 22:30
宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%
宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%
证券之星 · 12-08
宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%
11月26日宣泰医药现346.5万元大宗交易
证券之星 · 11-26
11月26日宣泰医药现346.5万元大宗交易
每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%
证券之星 · 11-09
每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%
11月4日宣泰医药发布公告，股东减持8.7万股
证券之星 · 11-04
11月4日宣泰医药发布公告，股东减持8.7万股
宣泰医药(688247)9月30日股东户数0.78万户，较上期减少3.25%
证券之星 · 10-30
宣泰医药(688247)9月30日股东户数0.78万户，较上期减少3.25%
宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%
智通财经 · 10-30
宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%
宣泰医药最新公告：奥拉帕利片拟中选第十一批全国药品集中采购
证券之星 · 10-29
宣泰医药最新公告：奥拉帕利片拟中选第十一批全国药品集中采购
10月22日宣泰医药发布公告，股东减持313.1万股
证券之星 · 10-22
10月22日宣泰医药发布公告，股东减持313.1万股
宣泰医药（688247）披露关于变更签字注册会计师的公告，10月21日股价上涨2.86%
证券之星 · 10-21
宣泰医药（688247）披露关于变更签字注册会计师的公告，10月21日股价上涨2.86%
宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号
智通财经 · 10-20
宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号
每周股票复盘：宣泰医药（688247）每股派息0.025元（含税）
证券之星 · 10-19
每周股票复盘：宣泰医药（688247）每股派息0.025元（含税）
宣泰医药公布国际专利申请：“恩扎卢胺药物组合物及其制备方法和用途”
证券之星 · 10-18
宣泰医药公布国际专利申请：“恩扎卢胺药物组合物及其制备方法和用途”
宣泰医药（688247）披露2025年半年度权益分派实施公告，10月14日股价下跌0.96%
证券之星 · 10-14
宣泰医药（688247）披露2025年半年度权益分派实施公告，10月14日股价下跌0.96%
宣泰医药（688247）股东南京市栖和创业投资合伙企业(有限合伙)质押1000万股，占总股本2.21%
证券之星 · 10-10
宣泰医药（688247）股东南京市栖和创业投资合伙企业(有限合伙)质押1000万股，占总股本2.21%
宣泰医药（688247）披露公司高级管理人员离任公告，9月30日股价上涨1.49%
证券之星 · 09-30
宣泰医药（688247）披露公司高级管理人员离任公告，9月30日股价上涨1.49%
宣泰医药(688247.SH)：西格列汀二甲双胍缓释片新增规格获批准
智通财经 · 09-26
宣泰医药(688247.SH)：西格列汀二甲双胍缓释片新增规格获批准
每周股票复盘：宣泰医药（688247）上半年净利降15.82%
证券之星 · 09-14
每周股票复盘：宣泰医药（688247）上半年净利降15.82%
宣泰医药（688247）3.11亿股限售股将于8月25日解禁，占总股本68.61%
证券之星 · 08-25
宣泰医药（688247）3.11亿股限售股将于8月25日解禁，占总股本68.61%
每周股票复盘：宣泰医药（688247）股东户数减少，控股股东承诺不减持
证券之星 · 08-24
每周股票复盘：宣泰医药（688247）股东户数减少，控股股东承诺不减持
暂无数据
公司概况
公司名称：
上海宣泰医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-25
主营业务：
上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、美沙拉秦肠溶缓释片、马昔腾坦片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。
发行价格：
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":10,"timestamp":1765522800000,"preClose":10.05,"halted":0,"volume":1853321,"delay":0,"changeRate":-0.005,"floatShares":453000000,"shares":453000000,"eps":0.2175,"marketStatus":"已收盘","change":-0.05,"latestTime":"12-12 15:00:00","open":10.12,"high":10.12,"low":9.98,"amount":18589400,"amplitude":0.0139,"askPrice":10.01,"askSize":48,"bidPrice":10,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.2175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.05,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":11.06,"lowLimit":9.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":3.47,"roa":"--","peRate":45.977011,"roe":"4.9%","epsLYR":0.28,"committee":0.48309,"marketValue":4533000000,"turnoverRate":0.0041,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-15。","afterMarket":{"amount":0,"volume":0,"close":10,"buyVolume":0,"sellVolume":0,"time":1765524837768,"indexStatus":"已收盘 12-12 15:30:00","preClose":10.05},"floatMarketCap":4533000000},"requestUrl":"/m/hq/s/688247/tweets","defaultTab":"tweets","newsList":[{"id":"2590502931","title":"宣泰医药（688247）披露募投项目延期公告，12月12日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502931","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590502931?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:30","pubTimestamp":1765549854,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，宣泰医药报收于10.0元，较前一交易日下跌0.5%，最新总市值为45.33亿元。该股当日开盘10.12元，最高10.12元，最低9.98元，成交额达1858.94万元，换手率为0.41%。近日，上海宣泰医药科技股份有限公司发布公告称，公司于2025年12月12日召开董事会，审议通过《关于募投项目延期的议案》，决定将“高端仿制药和改良型新药研发项目”达到预定可使用状态的时间由2025年12月延期至2027年12月。保荐机构对本次延期无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200042008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2589117359","title":"宣泰医药（688247）披露公司产品续约纳入国家医保目录，12月08日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589117359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589117359?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:24","pubTimestamp":1765203880,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，宣泰医药报收于10.37元，较前一交易日上涨0.39%，最新总市值为47.01亿元。该股当日开盘10.36元，最高10.4元，最低10.3元，成交额达1844.61万元，换手率为0.39%。近日，上海宣泰医药科技股份有限公司发布公告，其产品西格列汀二甲双胍缓释片以国谈续约形式纳入《国家基本医疗保险、生育保险和工伤保险药品目录》，医保支付标准维持3.47元/片不变，协议有效期为2026年1月1日至2027年12月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2586258562","title":"11月26日宣泰医药现346.5万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2586258562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586258562?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:52","pubTimestamp":1764150766,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日宣泰医药发生大宗交易，交易数据如下：大宗交易成交价格10.5元，成交33万股，成交金额346.5万元，买方营业部为民生证券股份有限公司苏州分公司，卖方营业部为广发证券股份有限公司总部。近三个月该股共发生1笔大宗交易，合计成交3300.0手。该股在过去半年内已有共计3.11亿股限售解禁股上市，占公司总股本的68.61%。截至2025年11月26日收盘，宣泰医药报收于10.5元，上涨0.19%，换手率1.08%，成交量4.88万手，成交额5200.03万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600027282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2582554864","title":"每周股票复盘：宣泰医药（688247）股东减持8.7万股至持股4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582554864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582554864?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:54","pubTimestamp":1762635250,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，宣泰医药报收于10.73元，较上周的10.98元下跌2.28%。期间股价下跌0.09%，截至11月4日收盘价为10.86元。原减持计划拟减持不超过700万股，实际减持321.8万股，计划已实施完毕。自2025年8月5日至11月4日，其通过集中竞价减持3,218,000股，占总股本0.7098%。减持完成后持股比例降至4.9808%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2580781580","title":"11月4日宣泰医药发布公告，股东减持8.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580781580","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580781580?lang=zh_cn&edition=full","pubTime":"2025-11-04 18:01","pubTimestamp":1762250509,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日宣泰医药发布公告《宣泰医药:关于持股5%以上股东减持计划时间届满暨减持股份结果公告》，其股东南京市栖和创业投资合伙企业(有限合伙)于2025年10月23日至2025年11月4日间合计减持8.7万股，占公司目前总股本的0.0192%，变动期间该股股价下跌0.09%，截止11月4日收盘报10.86元。股东增减持详情见下表：根据宣泰医药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400029077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2579183791","title":"宣泰医药(688247)9月30日股东户数0.78万户，较上期减少3.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579183791","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579183791?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816517,"startTime":"0","endTime":"0","summary":"证券之星消息，近日宣泰医药披露，截至2025年9月30日公司股东户数为7759.0户，较6月30日减少261.0户，减幅为3.25%。在化学制药行业个股中，宣泰医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，宣泰医药区间涨幅为5.71%，在此期间股东户数减少261.0户，减幅为3.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2579118194","title":"宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118194","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118194?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:29","pubTimestamp":1761812967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)披露2025年第三季度报告，公司前三季度实现营收3.31亿元，同比下降8.59%;归母净利润6346万元，同比下降31.45%;扣非净利润5388万元，同比下降36.64%;基本每股收益0.14元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"宣泰医药(688247.SH)发布前三季度业绩，归母净利润6346万元，同比下降31.45%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2579092205","title":"宣泰医药最新公告：奥拉帕利片拟中选第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2579092205","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579092205?lang=zh_cn&edition=full","pubTime":"2025-10-29 16:48","pubTimestamp":1761727687,"startTime":"0","endTime":"0","summary":"宣泰医药(688247.SH)公告称，公司参与了国家组织药品联合采购办公室组织的第十一批全国药品集中采购的投标，根据联采办于2025年10月28日发布的《全国药品集中采购拟中选结果公示》显示，公司产品奥拉帕利片拟中选本次集中采购。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900033931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2577736588","title":"10月22日宣泰医药发布公告，股东减持313.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577736588","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577736588?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:01","pubTimestamp":1761130884,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日宣泰医药发布公告《宣泰医药:关于持股5%以上股东减持至5%的权益变动提示性公告》，其股东南京市栖和创业投资合伙企业(有限合伙)于2025年8月5日至2025年10月22日间合计减持313.1万股，占公司目前总股本的0.6907%，变动期间该股股价下跌12.97%，截止10月22日收盘报10.87元。股东增减持详情见下表：根据宣泰医药2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200031505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2577828782","title":"宣泰医药（688247）披露关于变更签字注册会计师的公告，10月21日股价上涨2.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577828782","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577828782?lang=zh_cn&edition=full","pubTime":"2025-10-21 17:23","pubTimestamp":1761038599,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘，宣泰医药报收于10.78元，较前一交易日上涨2.86%，最新总市值为48.87亿元。该股当日开盘10.54元，最高10.78元，最低10.5元，成交额达3107.74万元，换手率为0.64%。近日，宣泰医药发布关于变更签字注册会计师的公告。时英浩1996年成为注册会计师，1994年开始从事上市公司审计；缪雪2023年成为注册会计师，2021年开始从事上市公司审计。本次变更不会对公司2025年度审计工作产生不利影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100026745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2576119839","title":"宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2576119839","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576119839?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:18","pubTimestamp":1760948300,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)公告，公司收到美国食品药品监督管理局(“FDA”)的通知，公司向美国FDA申报的西格列汀二甲双胍缓释片的简略新药申请(简称“ANDA””，即美国仿制药申请)获得暂时批准。西格列汀二甲双胍缓释片由MERCK SHARPDOHME公司开发，于2012年2月在美国获批上市，适用于改善成人2型糖尿病患者的血糖控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：西格列汀二甲双胍缓释片获美国FDA批准文号","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2576041595","title":"每周股票复盘：宣泰医药（688247）每股派息0.025元（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041595","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041595?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:18","pubTimestamp":1760818689,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，宣泰医药报收于10.47元，较上周的10.74元下跌2.51%。本周，宣泰医药10月16日盘中最高价报10.83元。本周关注点公司公告汇总：宣泰医药2025年半年度每股派发现金红利0.025元（含税），股权登记日为2025年10月20日。国泰海通证券股份有限公司作为保荐机构，对上海宣泰医药科技股份有限公司2025年半年度利润分配涉及的差异化分红事项出具核查意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2576064000","title":"宣泰医药公布国际专利申请：“恩扎卢胺药物组合物及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064000","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576064000?lang=zh_cn&edition=full","pubTime":"2025-10-18 05:19","pubTimestamp":1760735971,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示宣泰医药（688247）公布了一项国际专利申请，专利名为“恩扎卢胺药物组合物及其制备方法和用途”，专利申请号为PCT/CN2025/087109，国际公布日为2025年10月16日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来宣泰医药已公布的国际专利申请1个。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了2570.4万元，同比减24.54%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101800003723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2575321428","title":"宣泰医药（688247）披露2025年半年度权益分派实施公告，10月14日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575321428","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575321428?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:49","pubTimestamp":1760453356,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘，宣泰医药报收于10.36元，较前一交易日下跌0.96%，最新总市值为46.97亿元。该股当日开盘10.49元，最高10.59元，最低10.35元，成交额达3414.57万元，换手率为0.72%。近日，宣泰医药发布2025年半年度权益分派实施公告。根据公告，本次利润分配方案为每股现金红利0.025元（含税），股权登记日为2025年10月20日，除权（息）日和现金红利发放日均为2025年10月21日。现金红利将由中登上海分公司进行派发，部分股东由公司自行发放。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2574127104","title":"宣泰医药（688247）股东南京市栖和创业投资合伙企业(有限合伙)质押1000万股，占总股本2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574127104","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574127104?lang=zh_cn&edition=full","pubTime":"2025-10-10 18:37","pubTimestamp":1760092631,"startTime":"0","endTime":"0","summary":"证券之星消息，宣泰医药10月10日公开信息显示，股东南京市栖和创业投资合伙企业向深圳市高新投融资担保有限公司合计质押1000.0万股，占总股本2.21%。质押详情见下表：截止本公告日，股东南京市栖和创业投资合伙企业已累计质押股份2200.0万股，占其持股总数的85.28%。宣泰医药主营业务：自主实现高技术壁垒的仿制药的研发、产品注册申报、生产与销售;同时依托高标准的研发技术及产业化平台,为国内外新药企业及研发机构提供CRO/CMO服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000030777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2571932975","title":"宣泰医药（688247）披露公司高级管理人员离任公告，9月30日股价上涨1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571932975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571932975?lang=zh_cn&edition=full","pubTime":"2025-09-30 22:35","pubTimestamp":1759242923,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，宣泰医药报收于10.92元，较前一交易日上涨1.49%，最新总市值为49.5亿元。近日，上海宣泰医药科技股份有限公司发布公告称，公司于2025年9月30日收到副总经理吴华峰先生递交的书面辞职报告。其离任时间为2025年9月30日，原定任期至2026年5月30日。根据相关规定，辞职报告自送达董事会之日起生效。截至公告披露日，吴华峰先生未直接持有公司股份，不存在未履行完毕的承诺事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000040397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2570070238","title":"宣泰医药(688247.SH)：西格列汀二甲双胍缓释片新增规格获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2570070238","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570070238?lang=zh_cn&edition=full","pubTime":"2025-09-26 16:04","pubTimestamp":1758873896,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)公告，公司全资子公司江苏宣泰药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，西格列汀二甲双胍缓释片增加“每片含磷西格列汀50mg和盐酸二甲双胍500mg”规格的补充申请已获得国家药监局批准。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2567644139","title":"每周股票复盘：宣泰医药（688247）上半年净利降15.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567644139","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567644139?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:49","pubTimestamp":1757800152,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，宣泰医药报收于11.18元，较上周的11.04元上涨1.27%。本周，宣泰医药9月12日盘中最高价报11.26元。宣泰医药当前最新总市值50.37亿元，在化学制药板块市值排名106/150，在两市A股市值排名3296/5153。2025年上半年，公司实现营业收入2.196亿元，同比增长0.74%；净利润为4558.57万元，同比下降15.82%，主要因泊沙康唑肠溶片未中标集采及美沙拉秦肠溶片美国市场销售下滑。研发投入占比较上年同期下降，为11.70%。公司无重大违规行为，无重大风险未披露事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2562929892","title":"宣泰医药（688247）3.11亿股限售股将于8月25日解禁，占总股本68.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562929892","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562929892?lang=zh_cn&edition=full","pubTime":"2025-08-25 08:03","pubTimestamp":1756080198,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，宣泰医药于8月25日将有3.11亿股限售股份解禁，为公司首发原股东限售股份，占公司总股本68.61%。最近一年内，该股累计解禁226.7万股，占总股本的0.5%。宣泰医药主营业务：自主实现高技术壁垒的仿制药的研发、产品注册申报、生产与销售;同时依托高标准的研发技术及产业化平台,为国内外新药企业及研发机构提供CRO/CMO服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500001732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2561325510","title":"每周股票复盘：宣泰医药（688247）股东户数减少，控股股东承诺不减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2561325510","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561325510?lang=zh_cn&edition=full","pubTime":"2025-08-24 07:36","pubTimestamp":1755992177,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，宣泰医药报收于12.21元，较上周的12.35元下跌1.13%。本周关注点股本股东变化：截至2025年6月30日，宣泰医药股东户数减少至8020户，减幅为4.4%。公司公告汇总：控股股东上海联和投资有限公司承诺未来24个月不减持公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400002173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765617599253,"stockEarnings":[{"period":"1week","weight":-0.0319},{"period":"1month","weight":-0.0884},{"period":"3month","weight":-0.1034},{"period":"6month","weight":-0.0336},{"period":"1year","weight":-0.1518},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7759人(较上一季度减少3.25%)","perCapita":"58427股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是泊沙康唑肠溶片、美沙拉秦肠溶缓释片、马昔腾坦片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}